Search Results - "Chung, R.T."

Human Monoclonal Antibody MBL‐HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study by Chung, R. T., Gordon, F. D., Curry, M. P., Schiano, T. D., Emre, S., Corey, K., Markmann, J. F., Hertl, M., Pomposelli, J. J., Pomfret, E. A., Florman, S., Schilsky, M., Broering, T. J., Finberg, R. W., Szabo, G., Zamore, P. D., Khettry, U., Babcock, G. J., Ambrosino, D. M., Leav, B., Leney, M., Smith, H. L., Molrine, D. C.

“…Rapid allograft infection complicates liver transplantation (LT) in patients with hepatitis C virus (HCV). Pegylated interferon‐α and ribavirin therapy after…”
Get full text

Liver histologic spectrum in hepatitis B virus patients co-infected with the human immunodeficiency virus by Sterling, R, Kleiner, D.K, Abdus, W.S, Khalili, M, Ghany, M, Wong, D.K, Chung, R.T, Jain, M, Lisker-Melman, M

Get full text

Domino Liver Transplantation in Maple Syrup Urine Disease: A Case Report and Review of the Literature by Badell, I.R, Hanish, S.I, Hughes, C.B, Hewitt, W.R, Chung, R.T, Spivey, J.R, Knechtle, S.J

“…Abstract Background Improved outcomes have expanded the indications for liver transplantation, thus aggravating the already limited supply of donor organs…”
Get full text

An exploratory study to evaluate immune restoration after removal of viral antigen in adults with genotype 1a chronic hepatitis C virus infection treated with ombitasvir/oparitaprevir/ritonavir + dasabuvir and ribavirin for 12 weeks by Carlton-Smith, C, Holmes, J.A, Kim, A.Y, Dumas, E.O, Brown, J, Alatrakchi, N, Lauer, G.M, Silva, S.T, Tonnerre, P, Cohen, D.E, Zhang, H, Shulman, N.S, Chung, R.T

Get full text

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy by Grebely, J, Jacobson, I.M, Kayali, Z, Verna, E.C, Shiffman, M.L, Hyland, R.H, Stamm, L.M, Huang, K.C, Brainard, D.M, McHutchison, J.G, Pol, S, Chung, R.T, Bernstein, D.E, Dore, G

Get full text

LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target by Saxena, V, Koraishy, F.M, Sise, M, Lim, J.K, Chung, R.T, Liapakis, A, Nelson, D.R, Schmidt, M, Fried, M.W, Terrault, N

Get full text

1196 CLINICAL STUDY: METABOLIC INHIBITION OF VLDL AND ASSOCIATED HCV PRODUCTION BY A SINGLE ORAL DOSE OF NARINGENIN NANOCOMPLEX by Kim, A.Y, Levant, E, Reyor, L.L, Chung, R.T, Nahmias, Y

Get full text

P1161 PERI-TRANSPLANT TREATMENT WITH ANTI-HCV E2 HUMAN MONOCLONAL ANTIBODY MBL-HCV1 IN COMBINATION WITH A PROTEASE INHIBITOR RESULTS IN UNDETECTABLE HCVRNA IN THE EARLY POST-TRANSPLANT PERIOD by Curry, M.P, Smith, H.L, Chung, R.T, Schiano, T.D, Chapman, W.C, Mantry, P.S, Brown, K.A, Molrine, D.C

Get full text

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals by Lawitz, E, Kowdley, K, Curry, M, Reau, N, Nguyen, M, Kwo, P, Jacobson, I, Tran, T.T, Nahass, R, Hinestrosa, F, Herring, R, Bennet, M, Yang, J.C, Stamm, L.M, An, Di, Dvory-Sobol, H, Brainard, D.M, McHutchison, J.G, Schiff, E, Davis, M, Etzkorn, K, Chung, R.T, Pound, D, Rodriguez-Torres, M, Reddy, K.R, Younes, Z, Gane, E.J

Get full text

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION by Everson, G.T, Tran, T.T, Towner, W.J, Davis, M.N, Wyles, D, Nahass, R, McNally, J, Brainard, D.M, Han, L, Doehle, B, Mogalian, E, Symonds, W.T, McHutchison, J.G, Morgan, T, Chung, R.T

Get full text

763 NARINGENIN INHIBITS THE ASSEMBLY AND LONG-TERM PRODUCTION OF INFECTIOUS HEPATITIS C VIRUS (HCV) PARTICLES THROUGH A PPAR-MEDIATED MECHANISM by Nahmias, Y, Polyak, S.J, Chung, R.T

Get full text

1336 IL28B GENETIC ATTRIBUTABLE RISK IN HEPATITIS C-ASSOCIATED HEPATOCELLULAR CARCINOMA AND DECOMPENSATED LIVER DISEASE by O'Brien, T.R, Morgan, T.R, Pfeiffer, R.M, Chung, R.T, Lok, A.S, Shiffman, M.L, Dotrang, M, Sninsky, J.J, Bonkovsky, H.L

Get full text

835 TIME TO HCVRNA UNDETECTABILITY SUPERSEDES BASELINE FACTORS IN PREDICTING SVR IN PATIENTS WITH HCV GENOTYPE 1 by Shiffman, M.L, Chung, R.T, Hamzeh, F.M

Get full text

716 PROGNOSTIC GENE-EXPRESSION SIGNATURE FOR HEPATITIS C-RELATED EARLY-STAGE LIVER CIRRHOSIS by Hoshida, Y, Villanueva, A, Sangiovanni, A, Solé, M, Hur, C, Andersson, K.L, Chung, R.T, Gould, J, Kojima, K, Gupta, S, Taylor, B, Crenshaw, A, Gabriel, S, Minguez, B, Iavarone, M, Friedman, S.L, Colombo, M, Llovet, J.M, Golub, T

Get full text

Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B by Jourdain, G, Ngo-Giang-Huong, N, Harrison, L, Decker, L, Khamduang, W, Tierney, C, Salvadori, N, Cressey, T.R, Sirirungsi, W, Achalapong, J, Yuthavisuthi, P, Kanjanavikai, P, Ayudhaya, O.P Na, Siriwachirachai, T, Prommas, S, Sabsanong, P, Limtrakul, A, Varadisai, S, Putiyanun, C, Suriyachai, P, Liampongsabuddhi, P, Sangsawang, S, Matanasarawut, W, Buranabanjasatean, S, Puernngooluerm, P, Bowonwatanuwong, C, Puthanakit, T, Klinbuayaem, V, Thongsawat, S, Thanprasertsuk, S, Siberry, G.K, Watts, D.H, Chakhtoura, N, Murphy, T.V, Nelson, N.P, Chung, R.T, Pol, S, Chotivanich, N

“…(N Engl J Med 2018;378:911–923)Despite vaccination and administration of hepatitis B immune globulin at birth, mother-to-child transmission of hepatitis B…”
Get full text

253 ASSOCIATION OF HOST PHARMACODYNAMIC EFFECTS AND VIROLOGIC RESPONSE TO PEGINTERFERON ALFA-2A/RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C by Chung, R.T, Di Bisceglie, A, Poordad, F.F, Hassanein, T, Zhou, X, Lentz, E, Prabhakar, A, Hamzeh, F.M

Get full text

303 SHIFTS IN CHILD–PUGH SCORE IN PATIENTS COINFECTED WITH HIV-HCV UNDERGOING TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN ARE NOT PREDICTIVE OF HEPATIC DECOMPENSATION by Sulkowski, M, Chung, R.T, Slim, J, Bhatti, L, Sterling, R, Hassanein, T, Serrñao, R, Solà, R, Bertasso, A, Stancic, S, Rodriguez-Torres, M

Get full text

783 ASSOCIATION OF PRETREATMENT AND ON-TREATMENT FACTORS WITH NULL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN by DiBisceglie, A.M, Hassanein, T.I, Jeffers, L.J, Hamzeh, F.M, Lindsay, K.L, Chung, R.T

Get full text

3 POPULATIONAL ANALYSIS REVEALS A LINK BETWEEN COMPLEX VIRAL ESCAPE FROM CD8+ T-CELL RESPONSES AND PROTECTION IN HCV INFECTION by Kuntzen, T, Neumann-Haefelin, C, Lennon, N, Talal, A.H, Carlson, J, Brumme, C, Timm, J, Schmidt, J, Wunsch, K, Berical, A, Berlin, A.M, Adams, S, Young, S.K, Reyor, L.L, Kleyman, M, McMahon, C.M, Birch, C, Schulze zur Wiesch, J, Ledlie, T, Michael, K, Kodira, C, Roberts, A.D, Schneidewind, A, Lauer, G.M, Kim, A.Y, Rosen, H.R, Bihl, F, Cerny, A, Spengler, U, Brander, C, Galagan, J.E, Nusbaum, C, Walker, B.D, Lake-Bakaar, G.V, Daar, E.S, Jacobson, I.M, Gomperts, E.D, Edlin, B.R, Donfield, S.M, Chung, R.T, Marion, T, Birren, B.W, Marincola, F, Thimme, R, Carrington, M, Heckerman, D, Henn, M.R, Allen, T.M

Get full text

PL-07 HIV and TGF-β1 regulates HCV replication through multiple pathways by Lin, W.Y, Weinberg, E.M, Shao, R.X, Peng, L.F, Chung, R.T

Get full text